



PHARMACIA

Pressmeddelande

Framsteg i arbetet med konkurrens- myndigheterna beträffande samgåendet

Pfizer Inc. och Pharmacia Corporation rapporterar idag att framsteg gjorts i de pågående överläggningarna med Europakommissionens arbetsgrupp för företagssammanslagningar (MTF) respektive U.S. Federal Trade Commission (FTC) om det planerade samgåendet mellan de båda bolagen.

Antalet ouppklarade frågor från såväl MTF som FTC har minskat avsevärt, nu återstår bara ett litet antal frågor att klara upp, konstaterar bolagen.

"Våra överläggningar med amerikanska och europeiska myndigheter fortsätter att ge positiva resultat, och vi känner oss säkra på att affären kommer att kunna genomföras under första kvartalet 2003", sade Hank McKinnell, Pfizers koncernchef.

Pfizer har kallat till en extra bolagsstämma den 6 december för att kunna öka antalet aktier genom att emittera stamaktier i Pfizer i samband med det planerade förvärvet. Pharmacias bolagsstämma äger rum den 9 december. Båda stämmorna genomförs i Wilmington, Delaware.

Kontakt för media

Paul Fitzhenry, Pharmacia Corp. USA
Tel: +1 908 901 8771

#####

This release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectation and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained herein.

Readers are also urged to carefully review and consider the disclosures in Pfizer's and Pharmacia's various Securities and Exchange Commission ("SEC") filings, including but not limited to Pfizer's and Pharmacia's Annual Reports on Form 10-K for the year ended December 31, 2001, Pfizer's and Pharmacia's Quarterly Reports on Form 10-Q for the quarterly period ended March 31, 2002, Pfizer's and Pharmacia's Quarterly Reports on Form 10-Q for the quarterly period ended June 30, 2002, Pfizer's Quarterly Report on Form 10-Q for the quarterly period ended September 29, 2002, and Pharmacia's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2002.

This release may be deemed to be solicitation material in respect of Pfizer's proposed merger with Pharmacia. On October 17, 2002, Pfizer filed an amended registration

statement on Form S-4, with the SEC. On October 22, 2002, Pfizer filed a joint proxy statement/prospectus for Pfizer and Pharmacia, with the SEC. The joint proxy statement/prospectus was first mailed to Pharmacia shareholders on or about October 25, 2002. INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and securityholders will be able to receive the joint proxy statement/prospectus and other documents free of charge at the SEC's web site, www.sec.gov, Pfizer securityholders will be able to receive the definitive version of the joint proxy statement/prospectus and other documents free of charge by requesting them in writing from Pfizer Inc., 235 East 42nd Street, New York, New York 10017, Attention: Investor Relations, or by telephone: (212) 573-2688, and Pharmacia securityholders will be able to receive the definitive version of the joint proxy statement/prospectus and other

documents free of charge by requesting them in writing from Pharmacia Investor Relations at 100 Route 206 North, Peapack, New Jersey 07977, or by telephone at (908) 901-8000.

Pfizer and Pharmacia and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about the directors and executive officers of Pfizer and their ownership of Pfizer shares is set forth in the proxy statement for Pfizer's 2002 annual meeting of shareholders. Information regarding the interests of Pharmacia's directors and executive officers in the proposed merger is set forth in the definitive joint proxy statement/prospectus, filed on October 22, 2002, by Pfizer that was first mailed to Pharmacia shareholders on or about October 25, 2002.

Pfizer

Pfizer Inc. utvecklar, tillverkar och marknadsför ledande receptförskrivna läkemedel för människor och djur, liksom många av världens mest välkända konsumentvarumärken.

Pharmacia

Pharmacia Corporation är ett världsledande läkemedelsföretag med en produktion av innovativa läkemedel och andra produkter som räddar liv och förbättrar människors hälsa och välbefinnande. De 43 000 anställda i Pharmacia arbetar tillsammans med många andra intressenter för att öka livskvaliteten för människor runt om i världen och för att skapa lösningar för framtidens hälso- och sjukvård.